A report on 46 critically ill patients with coagulation dysfunction caused by cefoperazone sodium and sulbactam sodium
Dong Yizhu
Cai Liping
Liang Jianmin
Han Yibo
Huang Yifu
Abstract：Objective To explore the factors for coagulation dysfunction induced by cefoperazone sodium and sulbactam sodi-um(CSSS)in critically ill patients so as to provide basis for formulating strategies to prevent such adverse reactions.Methods A retrospective study method was used to select 46 hospitalized patients who were treated with cefoperazone and sulbactam sodium in the emergency intensive care unit and critical care medicine department of the Beihai People's Hospital from December 2022 to May 2024.The age,gender,liver and kidney function of the patients before the treatment,and medication dosage,international normal ratio(INR),prothrombin time(PT),platelet count,serum aspartate aminotransferase(AST),blood serum before and after medication clear alanine aminotransferase(ALT),serum gamma-glutamyl transferase(GGT),serum alkaline phosphatase(AKP),serum total bilirubin(TBIL),serum direct bilirubin(DBIL),serum indirect bilirubin determination(IDBIL),serum albumin(ALB),creatinine(CREA),urea(UREA),and patients'pre-medication diseases were statistically analyzed.Results Among the 46 patients,35 were male(76.09%),11 were female(23.91%),and 41 were elderly people over 60 years old(89.13%);patients with abnormal liver and/or kidney tests before taking the drug were more than normal patients(χ2=44.522,P<0.05);the levels of INR,PT,AST,GGT,CREA,and UREA were higher after the medication than before the medication(t=-21.123,-20.771,-11.997,-20.360,-9.219,-12.594,all P<0.05);the levels of PLT,ALT,AKP,TBIL,IDBIL,and ALB were lower after the medication than before the medication(t=10.907,2.799,2.417,5.880,9.260,9.700,all P<0.05);there was no significant difference in the level of DBIL before and after the medica-tion(t=1.033,P=0.305).Conclusion The main factors affecting coagulation dysfunction induced by CSSS in critically ill patients in this study include elderly individuals,males,pre-medication liver and kidney function status,and patient medication status.CSSS not only causes coagulation dysfunction in critically ill patients,but also exacerbates liver and kidney damage.Clinical medication requires close monitoring of coagulation function and liver and kidney function indicators.
Keywords：Cefoperazone sodium and sulbactam sodiumSevere diseaseCoagulation dysfunctionRisk factorAdverse reaction
Publication Date：2025-06-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 558-562 )